Cystic Fibrosis Market Research Report - Forecast till 2027

Cystic Fibrosis Market: Information By Treatment Method (Medication, Devices, Others) and By Region (North America, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/1293-CR | February 2021 | Region: Global | 62 Pages         

1 Introduction

1.1 Definition 8

1.2 Scope of Study 8

1.3 Research Objective 8

1.4 Assumptions & Limitations 9

1.4.1 Assumptions 9

1.4.2 Limitations 9

1.5 Market Structure 9

2 Research Methodology

2.1 Research Process 10

2.2 Primary Research 11

2.3 Secondary Research 11

3 Market Dynamics

3.1 Drivers 12

3.1.1 Introduction 12

3.1.2 Development of New Drugs and Therapies 12

3.1.3 Financial Support from CFF in Research & Development of CF Drugs. 12

3.2 Restraints 13

3.2.1 Introduction 13

3.2.2 High Cost of the Drugs and Treatment 13

3.3 Opportunities 13

3.4 Challenges 14

3.4.1 Awareness About the Rare Disease in the Developing Countries 14

4 Market Factor Analysis

4.1 Porter’s Five Forces Model 15

4.1.1 Bargaining Power of Suppliers 15

4.1.2 Bargaining Power of Buyers 15

4.1.3 Threat of New Entrants 16

4.1.4 Threat of Substitutes 16

4.1.5 Intensity of Rivalry 16

5 Cystic Fibrosis Market, By Treatment Method

5.1 Introduction 17

5.2 Medication 18

5.3 Devices 19

5.4 Other Treatments 20

6 Cystic Fibrosis Market, By Regions

6.1 Introduction 22

6.2 North America 24

Cystic Fibrosis Market, By Treatment Method

Cystic Fibrosis Market, By Regions

6.3 Europe 27

Cystic Fibrosis Market, By Treatment Method

Cystic Fibrosis Market, By Regions

6.4 Asia–Pacific 33

Cystic Fibrosis Market, By Treatment Method

Cystic Fibrosis Market, By Regions

6.5 Middle East & Africa 38

Cystic Fibrosis Market, By Treatment Method

Cystic Fibrosis Market, By Regions

7 Company Share Analysis

8 Company Profile

8.1 AbbVie 43

8.1.1 Company Overview 43

8.1.2 Product Overview 43

8.1.3 Financials 44

8.1.4 Key Developments 44.

8.2 Allergan PLC 46

8.2.1 Company Overview 46

8.2.2 Product Overview 46

8.2.3 Financials 46

8.2.4 Key Developments 46.

8.3 Chiesi Farmaceutici SpA 48

8.3.1 Company Overview 48

8.3.2 Product/Business Segment Overview 48

8.3.3 Financials 48

8.3.4 Key Developments 49

8.4 F. Hoffmann–La Roche AG 50

8.4.1 Company Overview 50

8.4.2 Product/Business Segment Overview 50

8.4.3 Financials 50

8.4.4 Key Developments 51

8.5 Gilead Sciences 52

8.5.1 Company Overview 52

8.5.2 Product Overview 52

8.5.3 Financials 52

8.5.4 Key Developments 52

8.6 Novartis AG 53

8.6.1 Company Overview 53

8.6.2 Product Overview 53

8.6.3 Financials 53

8.6.4 Key Developments 54

 

8.7 Pharmaxis Ltd 55

8.7.1 Company Overview 55

8.7.2 Product Overview 55

8.7.3 Financials 55

8.7.4 Key Developments 56

8.8 PTC Therapeutics 57

8.8.1 Company Overview 57

8.8.2 Product Overview 57

8.8.3 Financials 57

8.8.4 Key Developments 58

8.9 Vertex Pharmaceuticals Incorporated 59

8.9.1 Company Overview 59

8.9.2 Product/Business Segment Overview 59

8.9.3 Financials 59

9 List of Tables

TABLE 1 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 18

TABLE 2 GLOBAL CYSTIC FIBROSIS MEDICATION MARKET, BY REGION, 2020–2027 ($MILLION) 19

TABLE 3 GLOBAL CYSTIC FIBROSIS DEVICES MARKET, BY REGION, 2020–2027 ($MILLION) 20

TABLE 4 GLOBAL CYSTIC FIBROSIS OTHER TREATMENTS MARKET, BY REGION, 2020–2027 ($MILLION) 21

TABLE 5 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, 2020–2027 ($MILLION) 23

TABLE 6 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY COUNTRY, 2020–2027 ($MILLION) 24

TABLE 7 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 25

TABLE 8 US CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 26

TABLE 9 CANADA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 26

TABLE 10 EUROPE CYSTIC FIBROSIS MARKET, BY COUNTRY, 2020–2027 ($MILLION) 28

TABLE 11 EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 29

TABLE 12 GERMANY CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 29

TABLE 13 FRANCE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 29

TABLE 14 UK CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 30

TABLE 15 ITALY CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 30

TABLE 16 SPAIN CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 31

TABLE 17 REST OF WESTERN EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 31

TABLE 18 EASTERN EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 32

TABLE 19 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY COUNTRY, 2020–2027 ($MILLION) 34

TABLE 20 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 35

TABLE 21 AUSTRALIA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 35

TABLE 22 JAPAN CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 35

TABLE 23 CHINA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 36

TABLE 24 INDIA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 36

TABLE 25 REPUBLIC OF KOREA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 37

TABLE 26 REST OF ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 37

TABLE 27 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY REGION, 2020–2027 ($MILLION) 38

TABLE 28 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 39

TABLE 29 MIDDLE EAST CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 40

TABLE 30 AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 40

TABLE 31 CHIESI FARMACEUTICI SPA: KEY DEVELOPMENTS 49

TABLE 32 VERTEX PHARMACEUTICALS INCORPORATED: KEY DEVELOPMENTS 60

10 List of Figures

FIGURE 1 RESEARCH PROCESS OF MRFR 10

FIGURE 2 PORTER'S 5 FORCES ANALYSIS OF GLOBAL CYSTIC FIBROSIS MARKET 15

FIGURE 3 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020 & 2027 ($MILLION) 17

FIGURE 4 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, 2020 (%) 22

FIGURE 5 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY COUNTRY, 2020 (%) 24

FIGURE 6 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020 & 2027 ($MILLION) 25

FIGURE 7 EUROPE CYSTIC FIBROSIS MARKET, BY COUNTRY, 2020 (%) 27

FIGURE 8 EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020 & 2027 ($MILLION) 28

FIGURE 9 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY COUNTRY, 2020 (%) 33

FIGURE 10 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020 % 2027 ($MILLION) 34

FIGURE 11 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY REGION, 2020 (%) 38

FIGURE 12 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020 & 2027 ($MILLION) 39

FIGURE 13 CYSTIC FINROSIS MARKET SHARE, 2020 (%) 41

FIGURE 14 ABBVIE: RECENT FINANCIAL 44

FIGURE 15 ABBVIE: BUSINESS REVENUE, 2020 (%) 44

FIGURE 16 ABBVIE: GEOGRAPHIC REVENUE, 2020 (%) 45

FIGURE 17 ALLERGAN: RECENT FINANCIAL 46

FIGURE 18 ALLERGAN: BUSINESS REVENUE, 2020 (%) 47

FIGURE 19 ALLERGAN: GEOGRAPHIC REVENUE, 2020 (%) 47

FIGURE 20 CHIESI FARMACEUTICI S.P.A.: RECENT FINANCIALS 48

FIGURE 21 F. HOFFMANN-LA ROCHE AG.: RECENT FINANCIALS 50

FIGURE 22 F. HOFFMANN-LA ROCHE AG.: BUSINESS REVENUE 51

FIGURE 23 GILEAD SCIENCES: RECENT FINANCIAL 52

FIGURE 24 NOVARTIS AG: RECENT FINANCIALS 53

FIGURE 25 NOVARTIS AG: BUSINESS REVENUE, 2020 (%) 54

FIGURE 26 NOVARTIS AG: GEOGRAPHIC REVENUE, 2020 (%) 54

FIGURE 27 PHARMAXIS LTD: RECENT FINANCIALS 55

FIGURE 28 PTC THERAPEUTICS: RECENT FINANCIALS 57

FIGURE 29 PTC THERAPEUTICS: GEOGRAPHICAL REVENUE (%) 58

FIGURE 30 PTC THERAPEUTICS: R&D EXPENSES, 2020 (%) 58

FIGURE 31 VERTEX PHARMACEUTICALS INCORPORATED: RECENT FINANCIALS 59

FIGURE 32 VERTEX PHARMACEUTICALS INCORPORATED: BUSINESS REVENUE 60

FIGURE 33 VERTEX PHARMACEUTICALS INCORPORATED: GEOGRAPHICAL REVENUE 60

Cystic Fibrosis Market

Cystic mibrosis market size is projected to reach USD 32.89 Billion at a CAGR of 25.3% by the end of the forecast period

Segmentation

By Treatment Method Medication Devices
By Route of Administration Oral Inhaled
By Drug Class Pancreatic Enzyme Supplements Mucolytic Bronchodilators Antibiotics Cftr Modulators

Key Players

  • Allergan PLC
  • Chiesi Farmaceutici SpA
  • AbbVie
  • Hoffmann-La Roche AG
  • Gilead Sciences
  • PTC Therapeutics
  • Novartis AG
  • Vertex Pharmaceuticals Incorporated
  • Pharmaxis Ltd

Drivers

  • Growing Innovation to Cure the Disease can boost the industry
Speak to Analyst Request a Free Sample

Cystic Fibrosis (CF) Therapeutics Market overview


Based on the research analysis, the Cystic Fibrosis (CF) Therapeutics Market is expected to exhibit growth at a CAGR of 13.5% during the forecast period. As a result, the cystic fibrosis therapeutics market predicted revenue is USD 12,943.1 million over the forecast period. 


Cystic fibrosis, a genetic disorder that is progressive and genetic. It is characterized by gastrointestinal and respiratory tracts having unusual movement of sodium and chloride. This disease is not easily curable and can cause viscous secretion in the pancreas, intestines, liver and lungs. Cystic fibrosis treatments include gene therapy, physical therapy, nutritional support and physiotherapy. Apart from these, any symptomatic improvement and cellular interaction are treated using cystic fibrosis transmembrane conductance regulator (CFTR) modulators, mucolytics bronchodilators, pancreatic enzyme supplements. All these drugs can be taken orally or by inhalation with proper guidance and administration. 


In 2012, Vertext pharmaceuticals introduced a new drug called Kalydeco after a long experiment due to the increasing cases of cystic fibrosis. After the launch of the new medication, the market has seen a continuous development of new medicines and therapies regarding the treatment of CF. Financial backups to this experimentation and development have played a massive role in the growth of the market. 


Cystic Fibrosis (CF) Therapeutics Market dynamics


Increasing cases of cystic fibrosis and development and investment in diagnostic technologies by various governments are taking the market growth to further heights. Moreover, the high adoption of CFTRs as an alternative treatment all across the world also provides a boost to market growth. However, the expenses of treatment can have a hindering effect on the development of the market. But, many non-profiting organizations are participating, thus expected to provide a boost in the cystic fibrosis therapeutics market growth.


Drivers


The rising awareness about the disease and the availability of personalized drug therapy are expected to provide a driving force in the cystic fibrosis therapeutics market. Furthermore, the increasing availability of prosthetic molecules in curing cystic fibrosis is another significant market driving force. Additionally, governments of various countries are investing more in R&Ds is positively impacting the cystic fibrosis therapeutics market by enhancing the cystic fibrosis medication. 


Restrains


High expenses of treatment and limited opportunities in revenue are two restraining factors that the market of cystic fibrosis is expected to face against the growth. 


Opportunities


Various experiments and developments by the biotechnological and pharmaceutical sectors are creating significant opportunities in the Cystic Fibrosis (CF) Therapeutics Market in the forecast period. 


Challenges 


The two most challenging factors that the cystic fibrosis foundation therapeutics market is expected to counter during the forecast period are patient expiration and the introduction of generic drugs. 


Technological analysis


 


Segmentation overview


Based on the global Cystic Fibrosis (CF) Therapeutics Market, it is segmented into the following parts-



  • Route of administration

  • Drug Class

  • Region


By route of administration


Based on the route of administration, the cystic fibrosis therapeutics market is further segmented into-



  • Oral

  • Inhaled


By drug class


Based on the drug class, the cystic fibrosis therapeutics market is further segmented into-



  • Pancreatic Enzyme Supplements

  • Mucolytic

  • Bronchodilators

  • Antibiotics

  • CFTR modulators

  • Others 


By region


Based on region, the market is further segmented into-



  • North America

  • The U.S.

  • Canada

  • Mexico

  • Europe 

  • UK

  • Germany

  • France

  • Rest of Europe 

  • Asia-Pacific

  • China

  • India

  • Japan

  • Australia

  • Rest of Asia-Pacific

  • Latin America 

  • Brazil

  • Saudi Arabia

  • South Africa

  • Rest of Latin America


Regional analysis


Although cystic fibrosis can happen to any gender or race, there is evidence that mostly Caucasians get affected by this disease. Therefore, the rate of the disease is high in North America, Australia and Europe. However, it affects American Indians, Latinos, African and Middle Eastern populations as well. 


North America is expected to dominate the global cystic fibrosis therapeutics market during the forecast period among all these regions. This region has growing production of drugs that are FDA approved. In addition, demand in curing the disease leads the pharmaceutical markets to do continuous research and launch new products, thus expanding the market size. Among all the other North American countries, the United States is likely to see the highest cases of cystic fibrosis in coming years, which will accelerate the market growth of the United States. Based on the Cystic Fibrosis Foundation report, the total number of cystic fibrosis patients is more than 30,000, with 1000 cases added every year. 


Europe is vastly affected by cystic fibrosis, which is the most significant driving factor of the European market growth. Based on the European Cystic Fibrosis therapeutics market Society, in 2014, more than 35,500 people were already suffering from CF across the significant 26 countries in Europe. Increasing investments in R&D, government findings and support are likely to expand the regional market. 


The APAC Cystic Fibrosis (CF) Therapeutics Market is also expected to see huge growth due to the region's large population. In addition, the healthcare sectors going through ongoing developments and increasing R&D activities are expected to strengthen the market of the area. 


The cases of cystic fibrosis in the MEA are noticeably lower than in North American and European countries because of the racial factor. There is no particular reason behind this, but assumable it is low because of the non-European mixture. 


Competitive landscape


Experimentation and innovation are developing the growth of the cystic fibrosis (cf) therapeutics market. And along with this, the rising investment made in R&Ds is likely to expand the cystic fibrosis therapeutics in the development market. In addition, prominent participation and active collaborations of major key players are strengthening the market, and new players are contributing to the market development and competition. 


The market operating key players are currently focusing on the changing needs of the patients to address each problem related to it. For example, in April 2019, Vertex Pharmaceuticals Incorporated’s KALYDECO (ivacaftor) was approved by FDA i.e. Food and Drug Administration (US) with the aim of increasing the treatment options for millions of children suffering from cystic fibrosis(CF). This allowed the doctors for the first time to treat infants of six months old with a potential of modifying the course of cystic fibrosis.


Recent developments


In November 2020, a biopharmaceutical company Polyphor (Switzerland based), announced signing a funding agreement with the Cystic Fibrosis Foundation to advance inhaled murepavadin, new antibiotics, in CF (cystic fibrosis).


In December 2020- a development in a new antibiotic for a pathogen was made by the researchers of Hopkins University and Medicine. The pathogen is called Mycobacterium abscesses which is resistant to medication and dangerous for people with lung-related ailments or cystic fibrosis.


Major key players


There are many major key players in the cystic fibrosis (CF) therapeutics market who contribute to the market. new product developments and launches are hugely backing up the call. among all the key players, here is a list of the most prominent key players of the market. 



  • Allergan PLC

  • Chiesi Farmaceutici SpA

  • AbbVie

  • Hoffmann-La Roche AG

  • Gilead Sciences

  • PTC Therapeutics

  • Novartis AG

  • Vertex Pharmaceuticals Incorporated

  • Pharmaxis Ltd


 


Report overview



  • Market overview

  • Market dynamics

  • Drivers

  • Restrains

  • Opportunities

  • Challenges

  • Technological analysis

  • Segmentation overview

  • Regional analysis

  • Competitive landscape

  • Recent developments

  • Major key players



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2022: USD 12,943.1 Million
  • 2027: Significant Value
  •   CAGR   13.5% (2013-2022)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Treatment Method,
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Allergan PLC, AbbVie, Chiesi Farmaceutici SpA, Gilead Sciences, Hoffmann-La Roche AG, Novartis AG, PTC Therapeutics, Pharmaxis Ltd, Vertex Pharmaceuticals Incorporated
      Key Market Opportunities   Development of Pharmaceuticals and Biotechnological Sectors
      Key Market Drivers   Growing Innovation to Cure the Disease can boost the industry


    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Cystic fibrosis is a chronic, genetic disease that is bringing severe impact on the lives of about 70,000 people. As of now, the condition is not entirely curable.

    As per the analysis conducted by Market Research Future (MRFR), the Global Cystic Fibrosis Market is expected to expand at a CAGR of 13.5% and is likely to acquire the market value of USD 12,943.1 Million by 2022.

    Cystic fibrosis market is projected to grow at a 13.5% CAGR between 2013-2022.

    North America is expected to dominate the cystic fibrosis market.

    Cystic fibrosis market is predicted to touch USD 12, 943.1 million by 2022.

    The medication segment will lead the cystic fibrosis market.

    High cost of treatments and drugs may limit the cystic fibrosis market growth.